Safety warning: DAAs linked to hepatitis B risk

The hep C medicines have been associated with reactivation of the hep B virus, which can lead to liver failure and even death A TGA review has found evidence of an association between treatment of chronic HCV with DAA medicines and reactivation of HBV in a small number of patients with current or previous HBV

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Guild members approve new membership model
Next Forum: Codeine abuse in s2 products